Authors
Qianyi Chen, Hao Liu, Cien Sun, Ziming Wang, William C Cho, Jianfei Shen
Published in
Expert opinion on drug discovery. Pages 1-20. Jul 31, 2026. Epub Jul 31, 2026.
Abstract
Lung cancer remains the leading cause of cancer-related mortality worldwide, with lung adenocarcinoma (LUAD) being its most prevalent histological subtype, which is plagued by severe drug resistance and dismal long-term survival. Current treatment approaches are often limited by drug resistance and metastasis. Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, represents a promising novel therapeutic target to address these unmet clinical needs.
The authors of this narrative review synthesize the preclinical and translational evidence for ferroptosis-targeted lung cancer therapy and provide the reader with their expert perspectives on future development. Literature was retrieved from PubMed, Web of Science, Embase and China National Knowledge Infrastructure (CNKI) covering publications published between January 2018 and March 2026.
While ferroptosis induction effectively reverses therapeutic resistance in preclinical lung cancer models, its clinical translation is impeded by off-target toxicity, inconsistent subtype responses and the lack of validated predictive biomarkers. Ferroptosis agents will likely act as combinatorial adjuvants rather than monotherapies in the foreseeable future. Advancing subtype-selective compounds and multi-omics stratification signatures are essential to realize its clinical potential.
PMID:
42535898
Bibliographic data and abstract were imported from PubMed on 31 Jul 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 3
- Comments 0